Globalization of Internal R&D
Ironwood’s long-term goal is to get our medicines to appropriate patients around the world in the most efficient way possible. In some cases, this may be best achieved by accessing the infrastructure of collaborators with specific regional expertise. With our first internally-developed medicine, linaclotide, we’ve established the following network of partners to help us reach patients, and we may broaden this network in the future, either to support linaclotide or other programs.
LINZESS®* available in U.S. through 50/50 collaboration
in certain European countries through partnership
Under review by regulatory authority
for potential approval
LINZESS® approved in Japan through partnership